Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496312 | 0.98 | CETP (0.32) | TSHRTHRBCETPCNR1CNR2 | |
| Ethylene Glycol SCHEMBL5667972 | 0.92 | LMNA (0.38) | TSHRTHRBCETPCNR1CNR2 | |
| Ethylene Glycol SCHEMBL7118182 | 0.92 | LMNA (0.38) | TSHRTHRBCETPCNR1CNR2 | |
| SCHEMBL790521 | 0.91 | MEN1 (0.32) | CETPMEN1KMT2A | |
| Ethylene Glycol SCHEMBL8416280 | 0.91 | LMNA (0.37) | TSHRTHRBCETPCNR1CNR2 | |
| Ethylene Glycol SCHEMBL1509039 | 0.91 | LMNA (0.37) | TSHRTHRBCETPCNR1CNR2 | |
| SCHEMBL15663023 | 0.89 | TSHR (0.40) | TSHRTHRBSIRT2 | |
| SCHEMBL6930926 | 0.89 | TSHR (0.40) | TSHRTHRBSIRT2 | |
| SCHEMBL2952182 | 0.89 | TSHR (0.40) | TSHRTHRBSIRT2 | |
| SCHEMBL29039981 | 0.87 | TSHR (0.35) | TSHRTHRBCETPCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165940-A1 | METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS | HOFFMAN TECHNOLOGIES LLC | 2023-06-01 | — | — | US | claimed |
| EP-4132561-A1 | METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS | Hoffman Technologies LLC. (US) | 2023-02-15 | — | — | EP | claimed |
| EP-3681476-B1 | TRANSDERMAL FORMULATIONS | TYME INC (US) | 2022-09-14 | — | — | EP | claimed |
| CN-114945374-A | Pharmaceutical compositions and methods | 迪美公司 | 2022-08-26 | — | — | CN | claimed |
| EP-3934664-A1 | PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS | Hoffman Technologies LLC. (US) | 2022-01-12 | — | — | EP | claimed |
| WO-2021119096-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | TYME, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20210169903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | TYME, INC. | 2021-06-10 | — | — | US | claimed |
| US-20210008214-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2021-01-14 | — | — | US | claimed |
| US-20200405680-A1 | TRANSDERMAL FORMULATIONS | TYME, INC. (US) | 2020-12-31 | — | — | US | claimed |
| US-20200282014-A1 | PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2020-09-10 | — | — | US | claimed |
| WO-2020112766-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-06-04 | — | — | WO | claimed |
| US-20200163952-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-05-28 | — | — | US | claimed |
| US-20190192663-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2019-06-27 | — | — | US | claimed |
| WO-2019055747-A1 | TRANSDERMAL FORMULATIONS | TYME, INC. (US) | 2019-03-21 | — | — | WO | claimed |
| EP-3237013-A1 | TRANSDERMAL FORMULATIONS | Hoffman, Steve (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160199453-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-07-14 | — | — | US | claimed |
| US-20160193339-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-07-07 | — | — | US | claimed |
| WO-2016105530-A1 | TRANSDERMAL FORMULATIONS | HOFFMAN STEVEN (US) | 2016-06-30 | — | — | WO | claimed |
| EP-1448297-B1 | Method for Reducing Ligand-leakage from Affinity Chromatography Matrices | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-03-16 | — | — | EP | claimed |
| US-20110207326-A1 | SLURRY FOR POLISHING AND PLANARIZATION METHOD OF INSULATING LAYER USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-08-25 | — | — | US | claimed |